4 ms·
So in the clinic - what we usually do is a detailed neuropsychology battery. Also a patient history, but the neuropsych does provide some quantitative measures
by caycep 2y ago
So in the clinic - what we usually do is a detailed neuropsychology battery. Also a patient history, but the neuropsych does provide some quantitative measures.
If there's clear amnestic memory loss, verbal fluency decline and visualspatial processing decline, it's more probably Alzheimer's. vs. if there's other features in terms of frontaldysexecutive functioning, behavioral changes, etc, then you think FTD or possibly LBD if there's reports of early visual hallucinations.
Amyloid PETs are getting a bit better so there's that. Amyloid-negative PETs w/ amnestic memory loss are being lumped under this new LATE (Limbic-Predominant Age-Related TDP-43 Encephalopathy) but that definition always felt a bit...handwavey to me.
11-32 adults is a good pilot paper but you have to raise funding for Phase II and III trials.
- pedalpete 2y agoAwesome clarification! Thank you. We're not the researchers, we are developing the technology to support research. They are somewhat hamstrung with the currently available technology. There are other benefits to slow-wave enhancement, non-clinical and beyond dementia. It has been suspected this could play a role in prevention of AD, we were very suspicious (and still are a bit) that we could have a direct impact in treating AD. Having said that, the paper that looked at people with AD saw improvement in sleep, so even if we can help them subjectively feel less exhausted, that could be a quality of life benefit, even if non-clinical. I completely agree, that proving effectiveness in treatment is a long road, but we're going through a non-clinical use first. If the research works out, we can look into clinical use at a later date.
- throwaway852468 2y ago[dead]